How Lion's Mane Works in the Body: The Full Pharmacology

Lion's Mane (Hericium erinaceus)

4 documented pathways

Nerve growth factor is the mechanism everyone names, but it is one of at least four with published evidence behind them — and each runs on a different timescale. The popular claim that a single dose sharpens cognition within hours is the one part of this picture the trials do not support.

Li et al., Behavioural Neurology, 2018

4 pathways

NGF, BDNF, anti-inflammatory, and myelination each have published mechanistic evidence

49 weeks

longest Lion's Mane Alzheimer's trial — a pilot, with MMSE gains inside the treatment group

15 erinacines

identified to date (A–K and P–S); NGF-release activity attributed to erinacines A–I

Li et al., Behavioural Neurology, 2018

View as image ↗

The standard explanation for why Lion's Mane mushroom (Hericium erinaceus) affects cognition goes like this: bioactive compounds cross into the brain and trigger neurons to produce more nerve growth factor. That explanation is incomplete in two directions at once. It leaves out three other mechanisms with published evidence behind them — a mood-signaling cascade, an anti-inflammatory pathway, and a myelination pathway — and it quietly overstates how firmly the first step, getting into the brain, was ever established. For a broader introduction to what Lion's Mane is and what the clinical evidence shows overall, see what is Lion's Mane mushroom. This article focuses on the pharmacology: which pathways the compounds activate, how strong the evidence is for each, and how long each effect takes to appear.

The Gateway: What Is Actually Known About Reaching the Brain

Most compounds from food and supplements never reach the brain. The brain is protected by a specialized barrier (called the blood-brain barrier) that controls which molecules can enter from the bloodstream. Large molecules and water-soluble compounds are largely blocked. The barrier primarily admits small, lipid-soluble molecules, or those with a dedicated transport system.

Almost every popular account of Lion's Mane states that both of its major compound families — hericenones from the fruiting body, erinacines from the mycelium — cross this barrier. That statement is repeated so consistently that it reads as settled. It is worth looking at where it came from, because the evidence underneath it is younger and narrower than the confidence suggests.

Fact Check

Do hericenones and erinacines both cross the blood-brain barrier?

The claim

“Both of Lion's Mane's active compound families — hericenones and erinacines — have been confirmed to cross the blood-brain barrier and stimulate nerve growth factor production inside the brain.”

Repeated in supplement marketing and in review articles, where a single citation covering one compound is often carried forward as covering the whole class.

What research shows

Partly True

Li et al.'s 2018 review stated the opposite of the confident version: 'no direct evidence has yet shown that these compounds could pass through the blood-brain barrier,' and specifically noted that no study had shown erinacine A being absorbed, crossing into the brain, and localizing there. Direct pharmacokinetic evidence arrived afterwards, and it is erinacine-specific — rodent work measuring erinacines distributing into brain tissue after oral dosing, which later reviews cite when they describe the compounds as BBB-permeable.

The gap that remains is the hericenone half. Erinacines are produced only in the mycelium; the fruiting body was reported to contain none. So pharmacokinetic studies on erinacines cannot speak to hericenones, which is what most fruiting-body products actually supply. Reviews that cite erinacine data to support a claim about 'hericenones and erinacines' are extending the finding past what was measured.

Li et al., Behavioural Neurology, 2018 [ref 2]; Szućko-Kociuba et al., IJMS, 2023 [ref 16]

Li and colleagues, cataloguing the erinacine class in Behavioural Neurology in 2018, were explicit that the barrier question was open at that time.^[2] They recorded that fifteen erinacines (A–K and P–S) had been identified, that eight had documented neuroprotective properties, and that erinacine A was the only compound in the group whose central nervous system actions had been confirmed in rats — while calling for exactly the pharmacokinetic studies that had not yet been done.

Those studies followed. Rodent pharmacokinetic work has since measured erinacines being absorbed after oral dosing and distributing into brain tissue, with brain concentrations peaking hours after administration rather than minutes. Szućko-Kociuba and colleagues, reviewing the neurotrophic and neuroprotective effects of Hericium erinaceus in 2023, describe the erinacines as compounds capable of crossing the blood-brain barrier and inducing NGF expression in the brain on the strength of that work.^[16] Cornford and Charnley's 2025 review reaches a compatible conclusion, singling out erinacine-A-enriched preparations as showing both the highest bioactive potency among Hericium extracts and comparative ease of transport across biological barriers.^[14]

Once inside the brain, each compound class interacts with different targets and triggers different downstream effects. That divergence is what explains how a single mushroom can plausibly affect cognition, mood, inflammation, and nerve structure through distinct mechanisms rather than one.

For a detailed breakdown of the specific compounds in each class, including all fifteen erinacines and the "beyond" compounds like ergothioneine, see Lion's Mane bioactive compounds: hericenones, erinacines, and beyond.

Pathway 1: NGF Stimulation and Why the Cognitive Effects Take Weeks to Build

Nerve growth factor is a small protein, technically a neurotrophin, that neurons need to survive, maintain their connections, and form new synapses (the contact points through which signals pass between neurons). Adult brains do not produce large amounts of NGF by default. When neurons receive an NGF signal, they extend new connections, maintain existing ones, and resist damage. NGF itself cannot be given as a drug for brain conditions — it does not cross the blood-brain barrier and is rapidly broken down — which is precisely why compounds that prompt the brain to make its own have attracted attention.^[16]

Li et al.'s 2018 review is the source usually cited for the scope of this effect across the erinacine class. Its accounting is narrower than the way it is often quoted: of the fifteen erinacines identified, eight have documented neuroprotective properties, and the NGF-release activity specifically is attributed to erinacines A through I.^[2] Erinacine A is the most studied by a wide margin and the only one with confirmed central nervous system actions in rats at the time of that review.

Lai and colleagues, working in Malaysia and publishing in the International Journal of Medicinal Mushrooms in 2013, tested an aqueous extract of the fruiting body on NG108-15 neuroblastoma-glioma cells.^[1] The extract induced the cells to secrete NGF and promoted neurite outgrowth — neurites being the extensions neurons grow to connect with other cells. The most-quoted number from this study is a synergy result rather than a superiority one: combining 10 ng/mL of NGF with 1 μg/mL of mushroom extract produced the largest increase in neurite outgrowth, 60.6%, larger than either alone. The same study found the extract did not protect these cells against oxidative stress, and the authors concluded the preparation had neurotrophic but not neuroprotective activity. It is a cell-culture experiment, not a review and not an animal study, and it says nothing about the blood-brain barrier.

Tsai-Teng and colleagues moved the question into an animal model of Alzheimer's disease in 2016, giving erinacine-A-enriched mycelium orally to APPswe/PS1dE9 transgenic mice for 30 days.^[3] The treated animals showed reduced cerebral amyloid-beta plaque burden — specifically the non-compact portion of plaques — along with elevated insulin-degrading enzyme in the cortex, fewer plaque-activated microglia and astrocytes, an increased ratio of NGF to its precursor proNGF, and promoted hippocampal neurogenesis. Behaviourally, the animals recovered nesting activity, a daily-living measure in mice. This is an amyloid model, and the study did not measure tau pathology.

What does this produce in people? Mori and colleagues ran the trial that set the field's expectations for how long the cognitive effect takes to appear, and it is also the trial whose dose is most often misquoted.^[5]

Human trial

Mori, Inatomi & Ouchi (2009) · Phytotherapy Research

Population

30 Japanese men and women aged 50–80 with diagnosed mild cognitive impairment, randomized into two groups of 15

Intervention

Four 250 mg tablets containing 96% Yamabushitake (H. erinaceus) dry powder, taken three times daily — 3,000 mg of tablets per day — for 16 weeks

Comparator

Matched placebo tablets, parallel-group, double-blind

Finding

Scores on the Revised Hasegawa Dementia Scale were significantly higher than placebo at weeks 8, 12 and 16, and rose with duration of intake. Four weeks after intake stopped, scores fell significantly. Laboratory tests showed no adverse effects.

positive Small (n=30) and single-centre, but double-blind, placebo-controlled, and the source of the most-cited timeline in this literature. Note the dose: four 250 mg tablets three times daily — 3,000 mg per day — not the 1,000 mg figure that circulates widely.

Mori et al., Phytotherapy Research, 2009 [ref 5]

Li and colleagues extended this to a more severe population in a 2020 double-blind placebo-controlled pilot in mild Alzheimer's disease, using three 350 mg erinacine-A-enriched mycelium capsules daily over 49 weeks.^[6] The results need reading carefully, because the significant findings sit in different places. Mini-Mental State Examination scores improved significantly within the treatment group. The Cognitive Abilities Screening Instrument score declined significantly within the placebo group. Between the two groups, the significant differences were on Instrumental Activities of Daily Living and on contrast sensitivity. Several biomarkers — including apolipoprotein E4, brain-derived neurotrophic factor, and amyloid-beta peptide 1-40 — moved unfavourably in the placebo group over the study period, while the treatment group held steadier. That is a pattern of relative preservation rather than of reversal, and it is the more accurate way to describe the trial than saying biomarkers improved on treatment. Four participants withdrew with abdominal discomfort, nausea, or skin rash. It remains the longest Lion's Mane trial published, and its own authors present it as a pilot.

Phan and colleagues' 2015 review in Critical Reviews in Biotechnology is often cited as ranking Hericium erinaceus above other medicinal mushrooms.^[4] What it actually does is survey more than twenty brain-active culinary-medicinal mushrooms and at least eighty bioactive secondary metabolites, with Hericium erinaceus listed first among the species examined and among the best characterized. The activities catalogued across that literature include NGF synthesis, neurite outgrowth stimulation, reduction of amyloid-beta-induced neurotoxicity, anti-acetylcholinesterase, antioxidant and anti-neuroinflammatory effects. The review's own closing caveat is worth carrying forward: it focuses on in vitro evidence, and human clinical trials are needed.

The time course is pharmacologically expected. NGF stimulation triggers a cascade of gene expression changes, protein synthesis, and synapse formation that takes weeks to accumulate into measurable cognitive function. Any supplement promising a next-day cognitive shift through this specific mechanism is making a claim the biology does not support.

For the complete NGF research guide, see Lion's Mane and nerve growth factor: the complete research guide.

Pathway 2: BDNF Signaling and Why It Explains the Mood Effects

A second neurotrophin, brain-derived neurotrophic factor (BDNF), is the brain's primary mood-regulating growth factor. Its connection to depression is one of the leading biological frameworks in the field: reduced BDNF signaling is associated with depressive states, and many effective antidepressants raise BDNF activity over time. Like NGF, BDNF itself has poor blood-brain barrier permeability and a short half-life, which is why direct neurotrophin therapies have disappointed in clinical trials and why compounds that raise endogenous BDNF and TrkB receptor activity have become the more practical target.^[16]

Chiu and colleagues published the clearest mechanistic work on this in the International Journal of Molecular Sciences in 2018.^[7] They gave ethanolic erinacine-A-enriched Hericium erinaceus mycelium extract to mice at 100, 200, or 400 mg/kg per day for four weeks, with a fourteen-day repeated restraint-stress protocol layered on top. Stressed animals showed the expected changes: longer immobility in the tail suspension and forced swimming tests, altered open-arm behaviour, reduced norepinephrine, dopamine and serotonin, and elevated interleukin-6 and TNF-α. The extract significantly reversed these changes, most clearly at 200 and 400 mg/kg. Mechanistically, it activated the BDNF/TrkB/PI3K/Akt/GSK-3β pathway and blocked NF-κB signaling.

Does this translate to humans? Nagano and colleagues ran a small double-blind placebo-controlled trial in 2010 with 30 women, giving half Lion's Mane cookies and half placebo cookies for four weeks.^[8] The result is more qualified than it is usually reported. Depression scores on the CES-D and the Indefinite Complaints Index were significantly lower after intake than before it — a within-group change. Against placebo, only two specific items on the complaints index reached significance. The items covering concentration, irritability and anxiety moved in the expected direction but only as trends, not significant differences. What makes the study worth citing anyway is the authors' own reading: they concluded the effect suggested a mechanism different from NGF enhancement, which is the argument this article is making structurally.

Docherty and colleagues' 2023 pilot in Nutrients tested 1.8 g of Hericium erinaceus in 41 healthy adults aged 18–45, measuring both an acute timepoint and a 28-day one.^[9] Sixty minutes after a single dose, participants were significantly quicker on the Stroop task, a test of processing speed and interference control. After 28 days, subjective stress showed a trend toward reduction that did not reach significance. The authors also reported null and limited negative findings alongside these, and cautioned that the sample was small.

For the deeper look at serotonin and dopamine contributions to mood effects, see how Lion's Mane affects serotonin and dopamine pathways.

Pathway 3: How Lion's Mane Suppresses Brain Inflammation

Neuroinflammation — the chronic activation of the brain's immune cells — is a common driver of cognitive decline across multiple conditions. Alzheimer's disease, depression, traumatic brain injury, and normal aging all involve inflammatory processes in brain tissue that damage neurons over time. Microglia, the brain's resident immune cells, can shift from a neuroprotective mode to a neurotoxic one when chronically activated.

NF-κB is the master switch in this system: a transcription factor that, when active, drives expression of dozens of pro-inflammatory genes and the cytokines that damage neurons. Blocking it reduces the inflammatory cascade at its source rather than mopping up downstream.

The strongest evidence that Lion's Mane does this in a living animal comes from the same Chiu 2018 mouse study described above, which showed the erinacine-A-enriched extract blocking NF-κB signaling while simultaneously lowering the elevated IL-6 and TNF-α produced by chronic stress.^[7] Fu and colleagues' 2024 demyelination work, discussed in the next section, adds a second in vivo observation: reduced microglial and astrocyte activation and downregulated IL-1β expression in the brains of treated animals.^[13] And Tsai-Teng's Alzheimer's model showed the same directional effect on plaque-activated microglia and astrocytes.^[3]

Contato and Conte-Junior's 2025 narrative review in Nutrients places this in the wider antioxidant and anti-inflammatory context.^[11] Their account attributes the antioxidant activity to polysaccharides, terpenoids (the hericenones and erinacines), and phenolic compounds, acting by scavenging reactive oxygen species and inducing the body's own antioxidant enzymes, alongside the NGF-stimulating activity. The review's own conclusion is that clinical validation remains limited and that large-scale trials, standardized extraction, and pharmacokinetic characterization are the outstanding needs.

Phan et al.'s 2015 survey lists anti-neuroinflammatory activity among the effects documented across the mushroom literature it reviews, with the same in vitro caveat attached.^[4] The honest summary of this pathway is that the mechanism is well-described in animals and cells, plausible in humans, and not yet demonstrated by measuring inflammatory outcomes in a human trial.

Pathway 4: Myelination and What Erinacine S Adds

Myelin is the insulating sheath that wraps around nerve fibers. Without adequate myelin, nerve signals lose speed and accuracy, much as a fraying wire coating causes signal loss. Demyelinating conditions like multiple sclerosis destroy myelin systematically, and even normal aging produces gradual myelin degradation in some brain regions.

The fourth pathway is the least well-known: Lion's Mane appears to support myelin formation and protect the cells that produce it.

Kolotushkina and colleagues provided the earliest evidence in 2003, culturing cerebellar cells with Hericium erinaceus extract.^[12] Nerve and glial cells grew normally with no pathological or toxic effect, and the ultrastructure of the cells stayed intact. The relevant finding was about timing and rate: in the presence of the extract, myelination began earlier than in controls and proceeded faster. This was a regulatory effect on myelin genesis in culture, not a demonstration that a specific cell type had been targeted.

Preclinical

Fu, Chen & colleagues (2024) · Biomedicine & Pharmacotherapy

Population

Rats fed a cuprizone-containing diet to induce demyelination of the corpus callosum, plus mouse models of acute (6-week) and chronic (12-week) cuprizone demyelination

Intervention

Daily oral H. erinaceus mycelium extract, erinacine A, or erinacine S for three weeks alongside cuprizone; separately, erinacine S given during the final four weeks as post-treatment

Comparator

Cuprizone-exposed animals without extract

Finding

The mycelium extract and erinacine S preserved myelin and oligodendrocytes in the corpus callosum, reduced microglial and astrocyte activation, and downregulated IL-1β. Given as post-treatment, erinacine S inhibited demyelination and gliosis in both acute and chronic models and reduced anxiety- and depression-like behaviour.

preliminary Rodent-only, in a chemically induced demyelination model rather than an autoimmune one. No human trial has measured remyelination outcomes for Lion's Mane. The value of the result is mechanistic: it identifies a target — the myelin-forming cell — distinct from the neuron-focused NGF pathway.

Fu et al., Biomedicine & Pharmacotherapy, 2024 [ref 13]

Erinacine S is often described as newly discovered in 2024. It was in fact isolated from Hericium erinaceus mycelium in 2016 and characterized as a rare sesterterpene — structurally distinct from the other erinacines, which are cyathane diterpenoids — and its absorption and tissue distribution were studied in rats before Fu's demyelination work.^[2] What 2024 added was the oligodendrocyte target. Where erinacine A is characterized principally as an NGF inducer, erinacine S acts on the cells that manufacture myelin, which is a genuinely different mechanism rather than a variation on the first one.

Cornford and Charnley's 2025 review in Nutrition Research Reviews, which evaluated Hericium erinaceus as a possible future treatment for preventing and delaying Alzheimer's disease, drew on three human clinical trials and thirteen animal-model studies.^[14] It reported positive significant differences across behavioural, histological and biochemical assessments, singled out erinacine-A-enriched preparations as the most bioactive, and concluded that considerably more human trial data is required before the case is made.

For a deeper look at what these findings mean for conditions involving nerve damage, see Lion's Mane and multiple sclerosis: remyelination research.

The Acute Question: What a Single Dose Does and Does Not Do

A claim circulates widely that Lion's Mane produces measurable cognitive improvement within hours of a single dose — a finding that would be genuinely puzzling, since none of the four pathways above can act that fast. It is worth stating plainly what the two trials that tested this actually found, because the claim does not survive the reading. The more recent of the two is a 2025 crossover trial that is frequently cited as the proof of same-day effects.^[15]

Human trial

Surendran et al. (2025) · Frontiers in Nutrition

Population

18 healthy adults aged 18–35, randomized double-blind placebo-controlled crossover design

Intervention

A single acute dose of 3 g of a 10:1 H. erinaceus fruiting body extract, with assessment at baseline and 90 minutes post-consumption

Comparator

Matched placebo, within-subject crossover

Finding

No significant effect on the composite measures of global cognitive function or of mood. In the individual test analyses, participants improved on the pegboard task — a manual dexterity and psychomotor measure — at 90 minutes. The authors concluded that any benefit may be task or domain specific.

null This is the trial most often cited as showing acute cognitive and mood improvement. Its headline result is the opposite: the pre-specified composites were null, and a single psychomotor task moved. The authors' own recommendations were to study chronic supplementation, establish optimal dosing, and investigate mechanisms such as regional cerebral blood flow.

Surendran et al., Frontiers in Nutrition, 2025 [ref 15]

Docherty's 2023 pilot is the second trial in this pair, and it is the stronger of the two on this question — a significantly quicker Stroop performance sixty minutes after a single 1.8 g dose, in 41 participants.^[9] That is a real result. It is also one timed task, in a pilot study whose authors reported null and limited negative findings alongside it and asked for larger samples before anything was concluded.

Put together, the two trials support a narrow statement: in healthy young adults, a single dose has produced faster performance on individual speed-based tasks in two small studies, without moving broad measures of cognition or mood. That is a long way from same-day cognitive enhancement, and it does not require an undiscovered fifth mechanism to explain.

If the speed findings do hold up in larger trials, the interesting question is which mechanism could work that quickly, since the neurotrophic pathways cannot. Surendran's own suggestion — regional changes in cerebral blood flow — is the most concrete hypothesis on the table, and it is testable. Rodent pharmacokinetic data also argue against a fast neurotrophic route from a different direction: erinacine brain concentrations peak several hours after an oral dose, not within the sixty-to-ninety minute windows these trials measured.^[16] For now the honest position is that the acute signal is weak, domain-specific, and unexplained — which is a different thing from strong and unexplained.

Evidence position

1. Cell studiescompleted

   NGF secretion and neurite outgrowth in NG108-15 cells; myelination onset and rate in cerebellar cultures

2. Animal studiescompleted

   Amyloid, NGF/proNGF ratio and neurogenesis in transgenic mice; BDNF/TrkB/PI3K/Akt/GSK-3β and NF-κB in restraint-stressed mice; myelin and oligodendrocyte preservation in cuprizone rodents

3. Small human trialscurrent

   MCI (n=30, 16 weeks), mild Alzheimer's (49-week pilot), menopausal mood (n=30, 4 weeks), healthy young adults (n=41 and n=18, acute and 28-day)

4. Large RCTsmissing

   No adequately powered trial has been published for any of the four pathways

5. Meta-analysismissing

   Review-level syntheses exist, but intervention results across them are described as mixed rather than consistent

All four mechanisms are established in cells and animals. Human evidence exists but sits entirely in small trials — the largest cognitive trial enrolled 30 people and the longest was a 49-week pilot. Cha et al.'s 2024 review of 34 human studies found that dietary-pattern epidemiology favoured mushrooms consistently, while the ten intervention studies produced mixed results, with Lion's Mane the most-studied species and showing some enhancement of mood and cognition in middle-aged and older adults.

Cha et al., Neuroscience and Biobehavioral Reviews, 2024 [ref 10]; Li et al., Frontiers in Aging Neuroscience, 2020 [ref 6]

Cha and colleagues' 2024 review in Neuroscience and Biobehavioral Reviews is the most useful single check on how far this literature has actually come.^[10] Across 34 human studies, the 24 epidemiological ones showed a significant benefit of mushroom-containing dietary patterns on cognition and mood in both healthy and compromised populations. The ten intervention studies — the ones that actually administered mushrooms and measured outcomes — produced mixed results. Lion's Mane was the species most often investigated, showing some enhancement of mood and cognitive function in middle-aged and older adults. The review's closing call was for larger samples and more sensitive neurocognitive testing.

The Mechanism Timeline: When to Expect Which Effect

Because Lion's Mane operates through at least four distinct mechanisms with different biological timescales, the variation in trial results across different study durations makes more sense once the mechanisms are separated out.

Mechanism Map · Four Pathways, Four Clocks

The fastest pathway has the least human evidence.

Each bar spans when that mechanism would be expected to produce a measurable effect. Solid bars are timings observed in a human trial; hatched bars are mechanistic expectations resting on rodent or cell work alone.

The anti-inflammatory pathway is, in principle, the fastest. NF-κB inhibition can reduce inflammatory signaling within hours to days in a cell or an animal. No human trial has measured inflammatory outcomes on this timescale for Lion's Mane, so this ordering is a mechanistic expectation rather than a clinical observation.

Mood effects via the BDNF cascade appear to emerge across roughly one to four weeks. Nagano's four-week trial is the shortest human study showing mood movement, and even there the robust changes were within-group rather than against placebo. This timeline is consistent with BDNF-mediated neuroplasticity, where signaling triggers protein synthesis and structural change that take time to accumulate into a measurable mood outcome.

Cognitive effects via NGF stimulation accumulate over roughly eight to sixteen weeks of consistent use. Mori's 2009 trial gave 3,000 mg per day of tablets containing 96% dry powder and saw significant separation from placebo from week 8 onward, growing through week 16. Li et al.'s 2020 Alzheimer's pilot ran for forty-nine weeks. These are long timelines by supplement standards, but they are what one would expect from an intervention that works by maintaining neural infrastructure rather than by providing an acute stimulant effect.

Myelination effects likely require months and may be primarily protective rather than restorative. The Kolotushkina 2003 and Fu 2024 data are both preclinical, and no human trial has directly measured remyelination outcomes for Lion's Mane. The human timeline for this pathway is genuinely unknown.

One finding from Mori's 2009 trial deserves underlining: four weeks after participants stopped taking Lion's Mane, their cognitive scores had fallen significantly. Whatever state the mushroom sustains appears to require ongoing input rather than producing a permanent structural improvement. Lion's Mane is not a repair that gets completed. On the current evidence it behaves more like a maintenance signal.

Scope of this evidence

Moderate

This is pharmacology, not medical advice

Concern

Much of the mechanistic evidence on this page comes from cell cultures and rodents, and the human evidence comes from trials enrolling 18 to 41 participants. Several of those trials studied people with diagnosed mild cognitive impairment or mild Alzheimer's disease. Nothing here establishes that Lion's Mane treats, prevents, or slows any neurological or psychiatric condition in humans.

What the research says

Read pathway descriptions as accounts of what has been measured, in what species, at what dose — not as a basis for self-treating a diagnosed condition or for substituting a supplement for prescribed therapy. Where a human trial exists, this article states its size and duration so the weight of the evidence is visible.

Particularly relevant for: Anyone with a neurological or psychiatric diagnosis, anyone taking antidepressants or other centrally acting medication, anyone with a bleeding disorder or scheduled for surgery, and anyone pregnant or breastfeeding should speak with a clinician before using Lion's Mane. Four participants in the 49-week Alzheimer's pilot withdrew with abdominal discomfort, nausea, or skin rash.

What to do

If you are considering Lion's Mane alongside an existing treatment, bring the specific preparation and dose to your prescriber — mycelium-based erinacine products and fruiting-body hericenone products are not interchangeable in the evidence.

Li et al., Frontiers in Aging Neuroscience, 2020 [ref 6]; Mori et al., Phytotherapy Research, 2009 [ref 5]

For context on what this means across a person's lifespan, including the traditional uses that predate the mechanistic research by centuries, see Lion's Mane traditional uses vs. modern research. For how cultivation choices affect compound potency and which mechanisms are most active in a given product, see Hericium erinaceus cultivation and its impact on bioactive compound potency.

The Bottom Line

Hericium erinaceus has at least four documented pharmacological pathways: NGF stimulation via erinacines and hericenones, established in cells and animals and matched by cognitive improvement in small human trials over 8 to 16 weeks; BDNF/TrkB/PI3K/Akt/GSK-3β signaling, shown in restraint-stressed mice and consistent with modest human mood findings; NF-κB inhibition and antioxidant activity, demonstrated in vivo in rodents but never measured as an inflammatory outcome in a human trial; and oligodendrocyte protection via erinacine S, shown preclinically in cuprizone-exposed rodents. The blood-brain barrier step, often stated as settled for both compound families, rests on erinacine-specific rodent pharmacokinetics; no equivalent data exists for the hericenones that fruiting-body products supply. And the widely repeated claim that a single dose improves cognition within hours is not what the two acute trials found — one reported no significant effect on global cognition or mood, and the other a faster time on one task.

Frequently Asked Questions

How does lion's mane stimulate nerve growth factor?

Erinacines (from the mycelium) and hericenones (from the fruiting body) trigger neurons to produce more nerve growth factor (NGF), a protein that promotes neuron survival and growth. This matters because NGF itself cannot be given as a drug — it does not cross the blood-brain barrier and is broken down quickly — so compounds that prompt the brain to make its own are the practical route. Li et al.'s 2018 review in Behavioural Neurology records fifteen erinacines identified (A–K and P–S), eight with documented neuroprotective properties, and NGF-release activity attributed to erinacines A–I. Erinacine A is by far the most studied. The process takes weeks: NGF upregulation drives gene expression changes, protein synthesis, and structural remodeling that accumulate over time.

Does lion's mane increase BDNF?

In mice, yes. Chiu and colleagues (2018) gave erinacine-A-enriched mycelium extract to mice undergoing repeated restraint stress and showed activation of the BDNF/TrkB/PI3K/Akt/GSK-3β pathway alongside antidepressant-like behavioural changes, normalized serotonin, dopamine and norepinephrine, and reduced IL-6 and TNF-α. The effects were clearest at 200 and 400 mg/kg per day. This cascade is one of the better-studied routes in mood pharmacology, which is what makes its activation here mechanistically meaningful. No human trial has measured BDNF changes in response to Lion's Mane supplementation.

What signaling pathways does lion's mane activate?

Four have documented evidence. (1) NGF stimulation via erinacines and hericenones, promoting neuron survival and neurite outgrowth. (2) BDNF/TrkB/PI3K/Akt/GSK-3β signaling, shown in stressed mice and the most likely basis for mood effects. (3) NF-κB inhibition, which suppresses neuroinflammation at the transcription-factor level — demonstrated in vivo in the same 2018 mouse study and supported by reduced microglial and astrocyte activation in two other rodent models. (4) Oligodendrocyte protection via erinacine S, supporting myelination, shown in cuprizone-exposed rodents in 2024. All four are established in cells and animals; none has been confirmed by measuring the mechanism directly in a human trial.

How does lion's mane cross the blood-brain barrier?

More cautiously than most sources suggest. Li et al.'s 2018 review stated directly that no direct evidence had then shown these compounds crossing the barrier, and that no study had shown erinacine A being absorbed, crossing into the brain and localizing there. Rodent pharmacokinetic work published afterwards filled part of that gap, measuring erinacines distributing into brain tissue after oral dosing, and later reviews — including Szućko-Kociuba et al. (2023) — cite that work when describing the compounds as barrier-permeable. The important limit is that this evidence is erinacine-specific, and erinacines are produced only in the mycelium. No equivalent pharmacokinetic study has been published for the hericenones that fruiting-body products supply.

Does lion's mane work quickly or does it take weeks?

Weeks, on the current evidence. The two trials that tested a single dose in healthy young adults did not find broad acute effects: Surendran et al. (2025) found no significant effect on composite measures of global cognition or mood at 90 minutes, with improvement on a single pegboard task; Docherty et al. (2023) found significantly quicker Stroop performance at 60 minutes, in a pilot that also reported null and limited negative findings. NGF-mediated cognitive effects took eight to sixteen weeks to separate from placebo in Mori's 2009 mild cognitive impairment trial. Mood effects appeared around four weeks in Nagano's 2010 trial, though mostly as within-group change. When supplementation stopped in Mori's trial, scores fell significantly within four weeks.

Can lion's mane regenerate nerve cells?

The evidence supports growth promotion and protection rather than regeneration. The NGF pathway stimulates neuron survival, neurite outgrowth, and — in transgenic mice — hippocampal neurogenesis. The myelination pathway via erinacine S preserved myelin and oligodendrocytes in rodents exposed to a demyelinating agent. Whether any of this adds up to functional nerve regeneration in damaged human tissue has not been established; no human trial has measured remyelination or neurogenesis for Lion's Mane. The strongest human evidence remains in cognitive decline — mild cognitive impairment and mild Alzheimer's — where function improved over 16 to 49 weeks in trials of 30 people or fewer per arm.

Sources & References

1. 1RTHM-00295·Lai, Puei-Lene et al. (2013). “Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
2. 2RTHM-00973·Li, I-Chen et al. (2018). “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines..” Behavioural neurology.Study breakdown →PubMed →↩
3. 3RTHM-00452·Tsai-Teng, Tzeng et al. (2016). “Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice..” Journal of biomedical science.Study breakdown →PubMed →↩
4. 4RTHM-00397·Phan, Chia-Wei et al. (2015). “Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases: diversity, metabolite, and mechanism..” Critical reviews in biotechnology.Study breakdown →PubMed →↩
5. 5RTHM-00165·Mori, Koichiro et al. (2009). “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
6. 6RTHM-00631·Li, I-Chen et al. (2020). “Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study..” Frontiers in aging neuroscience.Study breakdown →PubMed →↩
7. 7RTHM-00505·Chiu, Chun-Hung et al. (2018). “Erinacine A-Enriched Hericium erinaceus Mycelium Produces Antidepressant-Like Effects through Modulating BDNF/PI3K/Akt/GSK-3β Signaling in Mice..” International journal of molecular sciences.Study breakdown →PubMed →↩
8. 8RTHM-00194·Nagano, Mayumi et al. (2010). “Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake..” Biomedical research (Tokyo.Study breakdown →PubMed →↩
9. 9RTHM-00821·Docherty, Sarah et al. (2023). “The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study..” Nutrients.Study breakdown →PubMed →↩
10. 10RTHM-00868·Cha, Sara et al. (2024). “A review of the effects of mushrooms on mood and neurocognitive health across the lifespan..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩
11. 11RTHM-00921·Contato, Alex Graça et al. (2025). “Lion's Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential-A Narrative Review..” Nutrients.Study breakdown →PubMed →↩
12. 12RTHM-00058·Kolotushkina, E V et al. (2003). “The influence of Hericium erinaceus extract on myelination process in vitro..” Fiziolohichnyi zhurnal (Kiev.Study breakdown →PubMed →↩
13. 13RTHM-00878·Fu, Jing-Ting et al. (2024). “Erinacine S, a small active component derived from Hericium erinaceus, protects oligodendrocytes and alleviates mood abnormalities in cuprizone-exposed rodents..” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.Study breakdown →PubMed →↩
14. 14RTHM-00922·Cornford, Nisha et al. (2025). “Hericium erinaceus: A possible future therapeutic treatment for the prevention and delayed progression of Alzheimer's disease? - A narrative review..” Nutrition research reviews.Study breakdown →PubMed →↩
15. 15RTHM-00952·Surendran, Geyan et al. (2025). “Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study..” Frontiers in nutrition.Study breakdown →PubMed →↩
16. 16RTHM-01798·Szućko-Kociuba, Izabela et al. (2023). “Neurotrophic and Neuroprotective Effects of Hericium erinaceus..” International journal of molecular sciences.Study breakdown →PubMed →↩